Trends, Challenges and Opportunities of Epigenetic Therapeutics in Cancer

3:00 PM - 4:00 PM (PDT), Tuesday, June 14, 2022

In recent times, the epigenetic drug discovery field has made substantial progress. So far, inhibitors targeting three epigenetic targets have been approved, including the first epigenetic inhibitor for solid tumors, and a plethora of molecules are progressing in clinical trials. Challenges of toxicity are being addressed by creative dosing regimens and combination therapies to ascertain positive outcomes in various cancer indications. Patient stratification for addressing the right population are being approached with innovative biomarker discovery strategies. Substantial literature evidence presents opportunities for epigenetic therapies in diverse malignancies such as neuro endocrine cancer.

Moderator
photo
President & Chief Executive Officer
Jubilant Therapeutics, Inc.
Speakers
photo
Institute Scientist
DFCI
photo
Senior Director
Pfizer La Jolla Laboratories
photo
VP, Head of Advanced Therapeutics
Lumanity